Details of the Drug Reposition

General Information of This Drug (ID: DME4RA8)

Drug Name
Amodiaquine   DME4RA8
Synonyms
Amodiachin; Amodiachinum; Amodiaquin; Amodiaquina; Amodiaquinum; Basoquin; CQA; Camochin; Camoquin; Camoquinal; Camoquine; Flavoquin; Flavoquine; Miaquin; Sunoquine; Amodiaquine hydrochloride; Amodiaquine USP24; SN 10751; AMODIAQUINE, FLAVOQUINE; Amodiaquina [INN-Spanish]; Amodiaquinum [INN-Latin]; CAM-AQ 1; CAM-AQI; Cam-AQ1; Camoquin (TN); Flavoquine (TN); SN 10,751; WR-002977; Amodiaquine (USAN/INN); Amodiaquine [USAN:INN:BAN]; Amodiaquine, ring-closed; S. N. 10751
Therapeutic Class
Antimalarials
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Withdrawn from market Indication(s)
Indication Name Indication ID ICD-11 Status REF
Malaria DISQ9Y50 1F40-1F45 Withdrawn from market [1]
------------------------------------------------------------------------------------
2 Preclinical Indication(s)
Indication Name Indication ID ICD-11 Status REF
Middle East Respiratory Syndrome (MERS) DIS5VPYU 1D64 Preclinical [2]
Severe acute respiratory syndrome (SARS) DISYW14W 1D65 Preclinical [2]
------------------------------------------------------------------------------------

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93.